2023-12-02 10:40:00
Since November 8, Novo Nordisk is no longer alone. The Dane will have to deal with competition from the American laboratory Eli Lilly, which has seen its anti-obesity drug approved in the United States. These revolutionary pills – Wegovy from Novo Nordisk, Zepbound from Eli Lilly – from new generations of diabetes treatments have proven their ability to make patients using them lose weight, opening up a gigantic potential market for them. As a result, the stock price of Novo Nordisk has soared by 58% in one year and that of Eli Lilly has soared by 90% since the beginning of March.
1701514672
#antiobesity #pill #war
Related posts:
New York issues law to guarantee rights of construction workers
First Branch of EVS: Specialized Electric Vehicle Maintenance Services in Ajman
New York Red Bulls vs Nashville SC - Live United States - United States MLS - 2023
Former SBU Officer's Toyota Land Cruiser Prado Explodes in Moscow: Investigation Underway
Police found a 78-year-old unconscious in his apartment in Eggendorf
hackers on the hunt for billions of missing cryptocurrencies
Quebec agrees with family physicians to strengthen front-line healthcare
National News Agency - Nasrallah: What was reported about sending fighters from Hezbollah to Ukraine...